How does 76X0's PS Ratio compare to its peers?

76X0 is expensive based on its Price-To-Sales Ratio (4.8x) compared to the peer average (4.3x).

How does 76X0's PS Ratio compare vs other companies in the European Life Sciences Industry?

76X0 is expensive based on its Price-To-Sales Ratio (4.8x) compared to the European Life Sciences industry average (3.9x).

What is 76X0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

76X0 is expensive based on its Price-To-Sales Ratio (4.8x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).

What is the Fair Price of 76X0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 76X0's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Standard BioTools (DB:76X0) - Stock Price, News & Analysis

76X0 Stock Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. More details

76X0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 16.43% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Standard BioTools Inc. Competitors

Evotec

XTRA:EVT

€1.9b

Gerresheimer

XTRA:GXI

€2.5b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.0b

Sartorius

XTRA:SRT3

€13.4b

Price History & Performance

Summary of all time highs, changes and price drops for Standard BioTools
Historical stock prices
Current Share Price	US$1.93
52 Week High	US$3.28
52 Week Low	US$1.59
Beta	1.64
11 Month Change	-14.60%
3 Month Change	12.21%
1 Year Change	-29.56%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-77.16%

Recent updates

Shareholder Returns

	76X0	DE Life Sciences	DE Market
7D	-13.1%	1.1%	-0.6%
1Y	-29.6%	10.6%	9.6%

Return vs Industry: 76X0 underperformed the German Life Sciences industry which returned -17.8% over the past year.

Return vs Market: 76X0 underperformed the German Market which returned 2.3% over the past year.

Price Volatility

Is 76X0's price volatile compared to industry and market?
76X0 volatility
76X0 Average Weekly Movement	12.0%
Life Sciences Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 76X0's share price has been volatile over the past 3 months.

Volatility Over Time: 76X0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1999	451	Adam Taich	www.somalogic.com

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.

Standard BioTools Inc. Fundamentals Summary

How do Standard BioTools's earnings and revenue compare to its market cap?
76X0 fundamental statistics
Market cap	€361.71m
Earnings (TTM)	-€119.03m
Revenue (TTM)	€74.61m

4.8x

P/S Ratio

-3.0x

P/E Ratio

Is 76X0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
76X0 income statement (TTM)
Revenue	US$81.72m
Cost of Revenue	US$97.89m
Gross Profit	-US$16.16m
Other Expenses	US$114.22m
Earnings	-US$130.38m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.69
Gross Margin	-19.78%
Net Profit Margin	-159.54%
Debt/Equity Ratio	0%

How did 76X0 perform over the long term?

See historical performance and comparison

76X0 Stock Overview

Rewards

Risk Analysis

Standard BioTools Inc. Competitors

XTRA:EVT

€1.9b

XTRA:GXI

€2.5b

XTRA:1SXP

€4.0b

XTRA:SRT3

€13.4b

Price History & Performance

Recent News & Updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 3Q 2022)

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.022 loss in 1Q 2022)

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

Less than half of directors are independent

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.64 loss in FY 2021)

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.30 loss in 3Q 2021)

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021)

SomaLogic Provides Revenue Guidance for the Full Year 2022

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

First quarter 2022 earnings released: US$0.022 loss per share (vs US$0.13 loss in 1Q 2021)

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings released: US$0.64 loss per share (vs US$0.81 loss in FY 2020)

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

Now 23% undervalued after recent price drop

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.55 loss per share

Director recently bought €136k worth of stock

No independent directors

Shareholder Returns

Price Volatility

About the Company

Standard BioTools Inc. Fundamentals Summary

4.8x

-3.0x

Earnings & Revenue